MedPage Today) -- A pembrolizumab (Keytruda) combination led to an overall survival (OS) boost in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer, according to results from the KEYNOTE-A18 trial...
112 N Bayshore Blvd #3 San Mateo, Ca 94401
650-544-0793
jamesfgraham111@gmail.com
Copyright © 2024 botnik. All Rights Reserved
